Sophoricoside from sophora japonica L. is efficacious as monotherapy or in combination with lenvatinib in hepatocellular carcinoma via targeting EGFR
Open Access
- 31 December 2025
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Abstract
Sophora japonica L. is a commonly used traditional Chinese medicine. Sophoricoside (Sop), the isoflavone glycoside obtained in Sophora japonica L., is demonstrated with various pharmacological activities, such as anticancer, anti-inflammation, and immunosuppression. To data, there is a lack of comprehensive research examining the biological activity of Sop in hepatocellular carcinoma (HCC). The present work focused on investigating effects of Sop on treating HCC and exploring its underlying mechanisms. Here, we found that the treatment of Sop suppressed HCC cell proliferation and survival, arrested HCC cell cycle in vitro, and attenuated HCC growth in vivo. Additionally, Sop combined with lenvatinib elicited the synergy to resist HCC both in vitro and in vivo. Mechanistically, Sop could directly interact with epidermal growth factor receptor (EGFR) to induce its degradation. Such augmented antitumor impact of lenvatinib by Sop was achieved by suppressing the AKT and STAT3 signaling pathways. In conclusion, Sop serves as the strong EGFR inhibitor and the potential natural anti-tumor drug, which can be the sensitizer of lenvatinib for treating HCC via EGFR-AKT/STAT3 signaling, presenting auspicious implications for novel anti-HCC treatment strategies.Keywords
Funding Information
- Natural Science Foundation of Xiamen (3502Z202373140)
- Natural Science Foundation of Xiamen (3502Z202373100)
- Key Project of Natural Science Foundation of Fujian Province (2022J02056)
- Key Project of Natural Science Foundation of Fujian Province (2023D001)
This publication has 24 references indexed in Scilit:
- New insights into the mechanism of resistance to lenvatinib and strategies for lenvatinib sensitization in hepatocellular carcinomaDrug Discovery Today, 2024
- Repression of LSD1/KDM1A activity improves the response of liver cancer cells to the lenvatinibDiscover Oncology, 2024
- Sophoricoside improved Crohn's disease-like colitis by inhibiting intestinal epithelial cell apoptosis through PI3K/AKT signalingInternational Immunopharmacology, 2024
- Taraxacum coreanum Nakai extract attenuates lipopolysaccharide-induced inflammatory responses and intestinal barrier dysfunction in Caco-2 cellsJournal of Ethnopharmacology, 2023
- Synergistic anticancer effect of flavonoids from Sophora alopecuroides with Sorafenib against hepatocellular carcinomaPhytotherapy Research, 2022
- Anticancer fungal natural products: Mechanisms of action and biosynthesisEuropean Journal of Medicinal Chemistry, 2020
- Lenvatinib: A Review in Hepatocellular CarcinomaDrugs, 2019
- Emerging functions of the EGFR in cancerMolecular Oncology, 2017
- Local and traditional uses, phytochemistry, and pharmacology of Sophora japonica L.: A reviewJournal of Ethnopharmacology, 2016
- Biotransformation of sophoricoside in Fructus sophorae by the fungus Schizophyllum communeBioresource Technology, 2012